Clinical Trial Search

Primary: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) — 2.0 percent change

Primary: Change of Frequency of Headache — 5.3; 7.5 score on a scale

Primary: Percentage of Participants Who Report 1 or More Adverse Events (AEs)- Healthy Participants — 50.0; 66.7; 50.0; 100.0 Percentage of Participants

Primary: Visual Analog Scale — 5.638; 5.050; 5.094; 4.894 Centimeters

Primary: Number of Subjects With Adverse Events — 8; 9 Participants

Primary: Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment. — -37.2; -35.7; -37.8; -37.3 score on a scale — p==0.974

Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T), Post Primary Vaccination — 176; 176 Participants

Primary: Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects — 2 Participants — p=0.824

Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees

Primary: Acceptance or Refusal of a Feeding Tube for Chronic Aspiration — 41; 45; 56; 57 Participants

Primary: Acceptability of Treatment Based on Survey Questionnaire Completed by Participants — 8.78; 8.23 score on a scale

Primary: Percentage of Participants Who Developed Clinically Significant Factor VIII (FVIII) Inhibitors During the Course of the Study — 21.74 Percentage of participants

Primary: Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721 — 2800; 2580; 10500 nanograms*hours/milliliter (ng*h/mL)

Primary: Lung Function — 35 Liters

Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants